A Randomized, Double-Blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B.

Trial Profile

A Randomized, Double-Blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 May 2018

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms NEPTUNE
  • Sponsors Roche
  • Most Recent Events

    • 08 May 2018 Results of a retrospective analysis of two randomised trials (WV16240 and WV19432; n=131) assessing the predictors of Peginterferon Alfa-2a (40KD) response, published in the Journal of Infectious Diseases
    • 09 Mar 2018 Results assessing seroconversion rates 5 years after completion of treatment, were published in the Alimentary Pharmacology and Therapeutics.
    • 01 Nov 2011 Results published in Hepatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top